Biography
Education
Institution | Degree | Dept or School | End Date |
---|---|---|---|
University of Chicago | M.D. | School of Medicine | 1996 |
Board Certifications
American Board of Radiology
Awards & Honors
Award | Conferred By | Date |
---|---|---|
Commitment to Patient Care Award | UCSF | 2012/2013 |
Lifetime Teaching Award | UCSF | 2012/2013 |
Educator of the Year | UCSF | 2009/2010 |
Clinical Expertise
Brain and Spinal Tumors
CyberKnife Irradiation for Lung and Skull Base
Esophageal Cancer
Intensity-modulated radiation therapy (IMRT)
Sarcoma
Stereotactic Lung Radiotherapy (SBRT)
Non-Small Cell Lung Cancer
Small-Cell Lung Cancer
External-beam Radiation
Bronchioloalveolar Carcinoma (BAC)
Program Affiliations
Thoracic Oncology Program
Department of Radiation Oncology
Helen Diller FamilyComprehensive Cancer Center
Sarcoma Program
Research Narrative
Dr. Gottschalk is involved in a number of clinical research projects. First, he has studied several methods of image-guided radiotherapy (IGRT), including, ultrasound, electronic portal imagining using gold seed fiducial markers and megavoltage cone-beam CT (MVCBCT). His research is one of the first to evaluate prostate bed motion in patients undergoing radiotherapy after prostatectomy. Dr. Gottschalk has investigated the use of MVCBCT for dose calculation and re-calculation as well as a novel high quality, low dose, imaging beam line. The dose re-calculation can be use for dose guided radiation therapy (DGRT).
Second, using the Radiation Oncology clinical database, Dr. Gottschalk has studied: the effectiveness of intraoperative radiation therapy (IORT) in the management of extremity sarcomas and renal cell carcinoma recurrences, permanent seed brachytherapy and high dose-rate brachytherapy (HDR) for the treatment of prostate cancer both as primary therapy and as salvage after radiation failures.
Third, he has been involved as a co-investigator in three trials: a Phase 2, Single-Center, Open-Label phase I/II study to evaluate safety and efficacy and Safety in patients who have resectable esophageal cancer and are treated with neoadjuvant cisplatin, irinotecan (CPT-11), ZD1839 (IRESSA®), and radiotherapy followed by surgical resection; a phase II study of radiation therapy, paclitaxel poliglumex and carboplatin in stage III non-small cell lung cancer; and a phase I/II open-label dose escalation study of anti-CTLA4 antibody with radiation for metastatic hormone refractory prostate cancer.
Forth, Dr. Gottschalk is involved with several RTOG (Radiation Therapy Oncology Group) studies. These have included several prostate cancer trials that investigate: high-dose vs standard-dose readiation for intermediate-risk prostate cancer; brachytherapy vs external-beam radiation plus brachytherapy for intermediate-risk prostate cancer; and standard fractionation vs hypofractionation for low-risk prostate cancer. Finally, as Director of the CyberKnife Radiosurgery Program Dr. Gottschalk oversees several of the stereotactic body radiosugery (SBRT) trials for lung and prostate cancer. He has a particular interest in the use of CyberKnife SBRT for the treatment of prostate cancer, kidney cancer, and lung cancer.
Research Interests
- Radiation in combination with chemotherapy and targeted agents
- Image-guided and adaptive radiation therapy
- Radiation sensitizers and protectors
Publications
- Tools and methods for cell ablation and cell inhibition in Caenorhabditis elegans.| | PubMed
- RIM and RIM-Binding Protein Localize Synaptic CaV2 Channels to Differentially Regulate Transmission in Neuronal Circuits.| | PubMed
- Deep match: A zero-shot framework for improved fiducial-free respiratory motion tracking.| | PubMed
- Structure-function analysis suggests that the photoreceptor LITE-1 is a light-activated ion channel.| | PubMed
- All-optical closed-loop voltage clamp for precise control of muscles and neurons in live animals.| | PubMed
- Rapid and reversible optogenetic silencing of synaptic transmission by clustering of synaptic vesicles.| | PubMed
- WormRuler: A software to track body length used to characterize a super red-shifted channelrhodopsin in Caenorhabditis elegans.| | PubMed
- Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial.| | PubMed
- Microbial Rhodopsin Optogenetic Tools: Application for Analyses of Synaptic Transmission and of Neuronal Network Activity in Behavior.| | PubMed
- Photoactivated Adenylyl Cyclases as Optogenetic Modulators of Neuronal Activity.| | PubMed